- Biopharmaceutical company Samsung Biologics Co. has signed CMO with GlaxoSmithKline.
- It has signed a deal worth $231 million.
- The contract is effective for eight years.
- Samsung Biologics will commercially produce GSK’s lupus treatment Benlysta.
South Korea’s Samsung Group on Friday announced that its biopharmaceutical business ....
Tags : SAMSUNG GROUP, SAMSUNG BIOLOGICS CO., GLAXOSMITHKLINE, CMO,